MPR Weekly Dose Podcast

ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia.

Warning about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrasting and a generic version of Tazorac. 

Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed in cognitive function.  

This week, news of the FDA’s vote on AMX0035, the novel ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.

Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; ‘rainbow fentanly’ targeting youth; and a device to treat chronic idiopathic constipation. 

USPSTF recommendations on statin use for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkeypox through fecal microbiota transplantation.

Novavax vaccine booster update; over-the-counter hearing aids; Priority Review for a castration-resistant prostate cancer combination treatment; first gene therapy approved for beta-thalassemia; FDA urges repeat at home COVID-19 testing to reduce risk of missing infection.

Emergency use authorization for intradermal administration of Jynneos; treatment approved for endometriosis pain; Amazon among the companies to receive a FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.

A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA addresses the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall is expanded for an over-the-counter laxative.

Emergency Use authorization for Novavax vaccine; the Pfizer-BioNTech vaccine gains adolescent approval; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.